Cargando…

Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin

Erlotinib belongs to the targeted cancer treatments acting through epidermal growth factor receptor inhibition. Papulopustular eruption is the most common cutaneous toxicity. The pathogenesis of the rash is not clear. There is no consensus on treatment. In this report, we describe a 73-year-old fema...

Descripción completa

Detalles Bibliográficos
Autores principales: Akoglu, Gulsen, Yavuz, Sibel Orhun, Metin, Ahmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900010/
https://www.ncbi.nlm.nih.gov/pubmed/27298507
http://dx.doi.org/10.4103/0253-7613.182887
_version_ 1782436568448892928
author Akoglu, Gulsen
Yavuz, Sibel Orhun
Metin, Ahmet
author_facet Akoglu, Gulsen
Yavuz, Sibel Orhun
Metin, Ahmet
author_sort Akoglu, Gulsen
collection PubMed
description Erlotinib belongs to the targeted cancer treatments acting through epidermal growth factor receptor inhibition. Papulopustular eruption is the most common cutaneous toxicity. The pathogenesis of the rash is not clear. There is no consensus on treatment. In this report, we describe a 73-year-old female patient who was referred to our outpatient clinic for evaluation and treatment of a widespread acneiform eruption. She was put on erlotinib therapy for 3 months for the treatment of lung adenocarcinoma. The patient has developed nonpruritic papules and pustules widespread over the body except the face for the past 2 weeks. Bacterial culture obtained from a pustule on the back grew methicillin-sensitive Staphylococcus aureus (SA). Histopathological examination of a papule demonstrated vacuolar degeneration of basal layer, prominent walls of vessels, a mixed infiltration of eosinophils, and lymphocytes and erythrocyte extravasation. The eruption was successfully treated with two weekly pulses of azithromycin 500 mg for 3 consecutive days. This case demonstrated that erlotinib may cause purpuric papular eruption secondarily infected with SA. Routine bacterial culture should be performed from pustules before any treatment.
format Online
Article
Text
id pubmed-4900010
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-49000102016-06-13 Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin Akoglu, Gulsen Yavuz, Sibel Orhun Metin, Ahmet Indian J Pharmacol Drug Watch Erlotinib belongs to the targeted cancer treatments acting through epidermal growth factor receptor inhibition. Papulopustular eruption is the most common cutaneous toxicity. The pathogenesis of the rash is not clear. There is no consensus on treatment. In this report, we describe a 73-year-old female patient who was referred to our outpatient clinic for evaluation and treatment of a widespread acneiform eruption. She was put on erlotinib therapy for 3 months for the treatment of lung adenocarcinoma. The patient has developed nonpruritic papules and pustules widespread over the body except the face for the past 2 weeks. Bacterial culture obtained from a pustule on the back grew methicillin-sensitive Staphylococcus aureus (SA). Histopathological examination of a papule demonstrated vacuolar degeneration of basal layer, prominent walls of vessels, a mixed infiltration of eosinophils, and lymphocytes and erythrocyte extravasation. The eruption was successfully treated with two weekly pulses of azithromycin 500 mg for 3 consecutive days. This case demonstrated that erlotinib may cause purpuric papular eruption secondarily infected with SA. Routine bacterial culture should be performed from pustules before any treatment. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC4900010/ /pubmed/27298507 http://dx.doi.org/10.4103/0253-7613.182887 Text en Copyright: © Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Drug Watch
Akoglu, Gulsen
Yavuz, Sibel Orhun
Metin, Ahmet
Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin
title Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin
title_full Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin
title_fullStr Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin
title_full_unstemmed Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin
title_short Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin
title_sort erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin
topic Drug Watch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900010/
https://www.ncbi.nlm.nih.gov/pubmed/27298507
http://dx.doi.org/10.4103/0253-7613.182887
work_keys_str_mv AT akoglugulsen erlotinibinducedpurpuricpapulopustulareruptiontreatedwithpulsedazithromycin
AT yavuzsibelorhun erlotinibinducedpurpuricpapulopustulareruptiontreatedwithpulsedazithromycin
AT metinahmet erlotinibinducedpurpuricpapulopustulareruptiontreatedwithpulsedazithromycin